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Abstract
Introduction: There are no known case reports of hepatic steatosis caused by oral fluoropyrimidines such as
capecitabine. With increasing use of capecitabine since its approval for the treatment of metastatic colon cancer in
2001, and more recently for adjuvant treatment of colon cancer and treatment of metastatic breast cancer, we can
anticipate increased recognition of potential toxicities associated with this 5-fluorouracil derivative.
Case presentation: We report the case of a 74-year-old Armenian woman who received capecitabine as adjuvant
treatment for colon cancer and subsequently developed abnormal liver biochemical tests and radiographic
findings in keeping with hepatic steatosis. There was complete reversal of liver enzyme abnormalities with
discontinuation of the drug and this patient represents a case of reversible liver injury due to capecitabine.
Conclusion: In this original case report, capecitabine use was associated with hepatic steatosis. It is important for
clinicians to recognize and monitor for this potential toxicity, which may be a cause of abnormal liver enzymes in
this patient population.
Introduction
Capecitabine is an orally administered precursor of
5-fluorouracil (5-FU), a fluoropyrimidine antimetabolite.
It is converted to 5-FU preferentially in tumor tissue,
and also in the liver, by way of a three-step enzymatic
cascade [1]. Capecitabine is a relatively new agent, with
FDA approval in 2001 for use as an alternative to the
Mayo Clinic 5-FU/folinic acid regimen for metastatic
colon cancer. It has since been approved for use in the
adjuvant treatment of colon cancer, as well as for meta-
static breast cancer.
Hepatic steatosis, a mild manifestation of non-
alcoholic fatty liver disease (NAFLD), may occur after
treatment with 5-FU. This has become a more recognized
complication in the era of hepatic surgery for colorectal
liver metastases, where hepatic steatosis is associated with
increased post-operative morbidity [2]. Peppercorn et al.
[3] found that 47% of patients with colorectal liver metas-
tases treated with systemic 5-FU and folinic acid had com-
puted tomography (CT) findings consistent with fatty
change. Another report described laboratory abnormalities
consistent with hepatic toxicity in 40% of patients who
received adjuvant therapy with 5-FU and levamisole after
undergoing surgical resection for Stage II or III colon can-
cer, with CT and biopsy evidence of steatosis in a few
cases [4]. There are, however, no known reports of liver
damage caused by oral fluoropyrimidines [5].
Case presentation
A 74-year-old Armenian woman with Stage III colon
cancer was treated in the adjuvant setting with capecita-
bine. Comorbid conditions included type II diabetes mel-
litus, hypertension and gastroesophageal reflux disease;
her concomitant medications included glyburide, metfor-
min, telmisartan, atenolol and lansoprazole. She had no
known hepatic disease, no history suggestive of Hepatitis
B or C exposure and did not drink alcohol. Baseline liver
enzymes and bilirubin were normal (AST 11 U/L [normal
<3 5U / L ] ,A L T7U / L[ n o r m a l<4 0U / L ] ,b i l i r u b i n
7 μmol/L [normal < 22 μmol/L]) and pre-treatment sta-
ging investigations including magnetic resonance imaging
(MRI) of liver (performed due to CT contrast allergy)
demonstrated no evidence of metastatic disease. Adju-
vant chemotherapy was initiated with capecitabine at
1000 mg/m
2 twice daily for 14 days every three weeks,
for a planned total of eight cycles. She developed Grade 2
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any medium, provided the original work is properly cited.diarrhea with the first cycle, with dose reduction to 750
mg/m
2 twice daily, which was well tolerated.
Her transaminases started to rise after the third cycle
of capecitabine (AST 44 U/L, ALT 57 U/L, bilirubin 18
μmol/L), with further elevation as well as mildly
increased bilirubin after the fourth cycle (AST 73 U/L,
ALT 101 U/L, bilirubin 24 μmol/L). She remained anic-
teric and had no symptoms of hepatic dysfunction.
Capecitabine was delayed while imaging investigations
were arranged to rule out the possibility of hepatic dys-
function due to liver metastases. Other causes of liver
disease such as viral hepatitis were considered and ruled
out with negative serology for Hepatitis B and C.
MRI of her abdomen demonstrated marked hepato-
megaly with severe fatty infiltration of the liver; the
s i g n i f i c a n ts i g n a ld r o pi no u t - o f - p h a s ec o m p a r e dt oi n -
phase imaging, which was not present on baseline scans,
confirmed severe hepatic steatosis (see Figure 1A-D).
There was no evidence of metastatic disease.
A clinical diagnosis of capecitabine-induced hepatic
steatosis was made. Capecitabine was held and after one
month, there was a decline in the transaminases and
bilirubin to normal (AST 27 U/L, ALT 35 U/L, bilirubin
13 μmol/L). After consultation with the hepatology ser-
vice, it was decided that the risk of disease recurrence
likely outweighed the risk of irreversible liver injury due
to capecitabine. After discussion with the patient and
her family, it was decided to cautiously rechallenge
her, with close monitoring of the liver enzymes. Transa-
minases and bilirubin remain normal after the first
rechallenge cycle (AST 30 U/L, ALT 41 U/L, bilirubin
9 μmol/L).
Figure 1 Capecitabine-induced hepatic steatosis in a 74-year-old woman. Dual-echo, chemical shift gradient-echo T1-weighted magnetic
resonance images show no evidence of hepatic steatosis which is demonstrated by the signal intensity of the liver on the in-phase (TR/TE, 150/
4.5) image (A) similar to that of the out-of-phase (150/2.3) image (B). Three-month follow-up magnetic resonance images after treatment with
capecitabine clearly show newly developed severe hepatic steatosis which is seen as a drop of the signal intensity of the liver on the out-of-
phase (150/2.3) image (C) compared with the in-phase (150/4.5) image (D).
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The spectrum of liver changes associated with fat accu-
mulation in hepatocytes is termed non-alcoholic fatty
liver disease (NAFLD) [2]. Although abnormal liver
function tests and radiographic findings may be sugges-
tive of NAFLD, histological evaluation remains the only
way to assess hepatocyte damage and to distinguish
‘simple’ steatosis from steatosis with inflammation, or
the more serious steatohepatitis, which can progress to
cirrhosis [6].
The classic findings of fatty liver associated with
abnormal liver tests and the improvement in transami-
nases upon drug interruption render NAFLD due to
capecitabine the most likely diagnosis in our patient. A
liver biopsy for histological confirmation was not pur-
sued in our patient, who fortunately had complete rever-
sal of liver enzyme abnormalities with discontinuation of
the drug, and therefore likely had a reversible mild form
of steatosis.
Conclusion
In this original case report, the patient presented repre-
sents a case of hepatic steatosis associated with the use
of capecitabine. It is important for clinicians to recog-
nize and monitor for this potential toxicity, which may
be a cause of hepatic dysfunction in this patient popula-
tion. This is especially important as these patients are
also at risk for hepatic metastases, which may present
similarly and need to be considered in the differential
diagnosis. With increased capecitabine use, we anticipate
more cases of NAFLD associated with this 5-FU
derivative.
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